Seroatlas · Human Serome Atlas

PRAMEF22

PRAME family member 22

Also known as: PRA22_HUMAN

Cross-references: UniProt · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: A3QJZ6
Gene: PRAMEF22
Canonical length: 481 aa

OverviewNCBI Gene

No narrative summary is available for PRAMEF22 in this catalog release; identity and structured annotations are shown without generated factual claims.

Canonical amino-acid sequenceUniProt

481 residues, UniProt reviewed canonical sequence.

>A3QJZ6|PRAMEF22
     1  MRMSLQAPRR LLELAGQSLL GDQALAISIL DELPRELFPP LFVEAFTSRR CEVLKVMVQA
    61  WPFPCLPLGS LMKTPDLEIL HYVVDGIDCL LAQKVRPRRW KLQVLELRDV DENFWTIWSG
   121  ARPLSCSPEA MSKRQTVEDC PRTGEKQPLK VFMDVCLKEK FMDEDLSFFS GWVQHRRGSV
   181  HLCCTKVVNY SMSILNFRNI LETVYPDSIQ VLEIWNMCWP CMIVEFSRYL SQMRNLRKLF
   241  ISDGCRYLLS SDSQEQLVAE FSSVLLRLEY LQMLYVRRVC FFRGHLDQLI RCLRSPLETL
   301  ALTYGFLEKV DLKCLPRYPS LSQLKQLNLS HGALRFIRLE PLRALLEKVA ATLQTLFLVD
   361  CGIRDSKLRV ILPALSCCSN LTTFCFHGND TSMDGLKDLL RHTGRLSNLS LETYPAPRES
   421  LDDRGRVISE LLTPLQAELM RILREVREPK RIFFGPVSCP CCGTSPTEQL EFNFCLWGRP
   481  A

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PRAMEF22 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.27

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.91
gnomAD pLI: 0
gnomAD missense Z: -0.36

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

ubiquitin-like ligase-substrate adaptor activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PRAMEF22 as an antibody target. Whether an autoantibody or antibody against PRAMEF22 could matter depends on whether native PRAMEF22 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PRAMEF22 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label PRAMEF22 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...